Table 7.
Recurrence rates of RLA versus surveillance or chemotherapy in studies with non-seminomatous GCT patients in cSI [25, 34]
![Recurrence rates of RLA versus surveillance or chemotherapy in studies with non-seminomatous GCT patients in cSI [25, 34]](https://karger.silverchair-cdn.com/karger/content_public/journal/uin/105/3-4/10.1159_000510407/2/000510407_t07.png?Expires=1757228364&Signature=m3UNl5UsxMYRJC93lflutTh7-IaZbY5uUn08pvBIDVSXjLVwo-1uQ2K~19WNxvY4Uh8B1yNM7E332MSWAvMgPPdqdoZYW~n4s9R82lZCg03LOxM5436kqTa5CLWYOXpU~7zipAH6twNTPHzB5azrvKeahLEwpg4bpxAUb6f6PJScyKHg3trxfZ3LGU1ix2-1QSYBgKOac4LLVj3ZjfRtxWez8fNNKtRQyQCkxoEyGaGLdRK-egy5sQvBeMuZrv2--QtBWyxfzjPiPN7V1q5Pv3cp5k9n6vNhXlG0fK0N0fOJ5Qf109WC1~WtezecWEcqnIQn7TzfqhDbqv2pfyZObQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Recurrence rates of RLA versus surveillance or chemotherapy in studies with non-seminomatous GCT patients in cSI [25, 34]
